GB2454480A — Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

USPTO Abstract

A composition comprising levodopa (L-dopa) for the treatment of diseases and disorders of the central nervous system, such as Parkinson's disease, wherein the composition is administered via pulmonary inhalation and provides a therapeutic effect within 10 minutes of administration. The composition may be used in combination with or comprise one or more additional therapeutic agents including a peripheral DOPA decarboxylase inhibitor, a catechol-o-methyl transferase (COMT) inhibitor or a monoamine oxidase type B (MAOB) inhibitor. In addition to the therapeutic agent(s) the composition may include other materials such as additives including amino acids, metal stearates, phospholipids, lecithin, colloidal silicon dioxide and sodium fumarate and/or inert excipients including sugar alcohols, polyols, crystalline sugars, inorganic salts, organic salts, polysaccharides and oligosaccharides. The composition may be administered when needed as a form of rescue therapy through use of a dry powder inhaler, a pressurised meter dose inhaler (pMDI) or via a nebulised system.